New applications of gene editing technology: Eligo and Kantonsspital St. Gallen formed a strategic alliance to address inflammatory heart disease through in vivo gene editing

On September 13, 2022, gene-editing company Eligo Bioscience ("Eligo") and Kantonsspital St.

Eligo, a global leader in microbiome gene editing therapy, is advancing a highly differentiated precision drug pipeline to address unmet medical needs

Through proprietary in vivo gene editing technology, Eligo precisely modifies genes from bacteria that encode disease-driven peptide mimimetics so that these peptides are not immunogenic, thereby eliminating a disease exacerbating factor

Kantonsspital St.

The 21st century is an era of vigorous life sciences, and gene editing has had a profound impact on

From the perspective of technology development, gene editing has experienced the iterative development of zinc finger nucleases (ZFNs), transcriptional activator effector nucleases (TALENs) and CRISPR technology, making the application scenarios more diversified

The medical research of gene editing is still in its preliminary stages, and there are four main problems:

Effectiveness

The way of

Off-target problem

Ethical and security issues

In 2020, the global market size of gene editing services is expected to be 3.

Source: